UCLA Well being Jonsson Complete Most cancers Heart researchers and physicians who focus on treating sufferers with radiation therapies will current information on the most recent radiation oncology analysis and medical trial outcomes on the 66th annual American Society for Radiation Oncology (ASTRO) assembly in Washington D.C., Sept. 29 to Oct. 2.
The annual assembly, which is the main assembly in radiation oncology, will function 23 abstracts from UCLA investigators that spotlight key areas of radiation oncology, together with new analysis in subspecialties starting from survivorship, lung most cancers/thoracic malignancies, physics, sarcoma, gastrointestinal most cancers, genitourinary most cancers, gynecological most cancers, pediatric most cancers and variety, fairness and inclusion in healthcare.
“Our workforce is proud to current analysis that pushes the boundaries of what is attainable in radiation oncology,” stated Dr. Michael Steinberg, professor and chair of Radiation Oncology on the David Geffen College of Drugs at UCLA and director of Medical Affairs on the UCLA Well being Jonsson Complete Most cancers Heart. “These research, starting from progressive approaches in chemoradiotherapy and symptom monitoring to developments in MRI-guided radiotherapy, underscore our dedication to enhancing affected person outcomes and shaping the way forward for most cancers therapy.”
Highlights of noteworthy shows at ASTRO which can be led by UCLA investigators embody:
Summary 1071: MicroRNA-Based mostly Germline Biomarkers of Pathologic Full Response to Neoadjuvant Chemoradiotherapy in Rectal Most cancers
A workforce of researchers led by Dr. Joanne Weidhaas, professor of radiation oncology, vice chair of molecular and mobile oncology and director of translational analysis on the David Geffen College of Drugs at UCLA, recognized a genetic signature that might assist predict which sufferers with domestically superior rectal most cancers are more than likely to attain a pathologic full response following therapy with a mixture of chemotherapy and radiotherapy. Previous to this examine, there has not been a molecular based mostly assay to foretell which sufferers are more than likely to profit from chemoradiotherapy to assist with therapy choice. The examine, performed with 90 sufferers with rectal most cancers, targeted on microRNA-related single nucleotide polymorphisms (miSNPs), that are genetic variations that may disrupt microRNA signaling, a vital course of in regulating gene expression. By analyzing mirSNPs at the side of medical variables, together with age, tumor stage and KRAS mutation standing, the researchers developed a predictive mannequin with a powerful capability to determine sufferers who would obtain an entire response the place no viable tumor cells stay after therapy. The predictive mannequin, constructed utilizing superior statistical methods, outperformed fashions based mostly solely on medical components. This mannequin gives a extra personalised method that might determine sufferers more than likely to reply to this therapy method, and will probably assist them keep away from pointless surgical procedure. The workforce plans to validate these findings in a bigger affected person cohort and additional examine the mirSNP signature’s capability to foretell therapy toxicity.
Weidhaas will current the findings throughout Session: QP 13-GI 4: GI Cancers: From high to backside on Tuesday, Oct. 1 at 4pm EST in room 152.
Summary 317: Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Physique Radiotherapy for Prostate Most cancers: 2-12 months Outcomes from the MIRAGE Randomized Medical Trial
In a secondary evaluation of a randomized section 3 medical trial evaluating two strategies of guiding stereotactic physique radiotherapy (SBRT) for prostate most cancers, researchers discovered sufferers handled with MRI steerage had fewer long-term unwanted effects and higher high quality of life associated to bowel and sexual well being in comparison with these handled with CT steerage. Prostate most cancers is without doubt one of the most typical cancers amongst males, and radiotherapy is a typical therapy possibility, particularly for these with localized illness. Nevertheless, the unwanted effects of therapy will be extreme and long-lasting, affecting a affected person’s urinary, bowel, and sexual perform. The workforce, led by Dr. Amar Kishan, govt vice chair of radiation oncology on the David Geffen College of Drugs at UCLA, discovered sufferers handled with MRI-guided SBRT skilled considerably fewer grade 2 or larger genitourinary and gastrointestinal poisonous results in comparison with these receiving CT-guided therapy. Particularly, solely 27% of MRI-guided sufferers reported late genitourinary toxicity-;resembling urinary incontinence and irritation-;in comparison with 51% within the CT-guided group. Equally, gastrointestinal toxicity-;resembling bowel issues-;was decreased to only 1.4% with MRI steerage, versus 9% with CT steerage. The examine adopted sufferers for 2 years after therapy, making it one of the vital complete evaluations of MRI-guided SBRT to this point.
Kishan will current the findings throughout Session: SS 38-GU 2: Optimizing Therapeutic Ratio in Prostate Most cancers on Tuesday, Oct. 1 at 2:30pm EST in room 202.Â
Summary 122: Symptom Monitoring with Affected person-Reported Outcomes throughout Definitive Radiation Therapy
On this section 2 examine, led by Dr. Ann Raldow, affiliate professor of radiation oncology on the David Geffen College of Drugs at UCLA, investigators assessed whether or not utilizing a cellular app, referred to as mPROS, to report signs improves the standard of life for sufferers with most cancers present process radiation remedy. Whereas using patient-reported outcomes has proven advantages in enhancing medical outcomes for sufferers receiving chemotherapy, its results within the context of radiation remedy haven’t been properly established. This examine sought to fill that hole by evaluating sufferers who used the mPROS app to report signs with these receiving normal care. The examine concerned 59 sufferers receiving definitive radiation remedy alongside chemotherapy for varied cancers, together with gastrointestinal, gynecological, lung, central nervous system and head and neck cancers. Members had been randomly assigned to both the experimental group, the place they used the mPROS app, or the management group. Sufferers within the experimental group had been inspired to report signs not less than weekly by way of the app, with extreme or worsening signs routinely alerting their medical workforce. Researchers then measured the impression of this method on health-related high quality of life utilizing a validated questionnaire at first, finish and three months after finishing radiation remedy. The outcomes confirmed that there have been no important variations in bodily or psychological well being outcomes between the 2 teams. Nevertheless, sufferers utilizing the mPROS app expressed excessive satisfaction, feeling extra engaged of their care and discovering the app useful in monitoring their signs. The vast majority of members within the experimental group additionally reported that they might suggest the app to different sufferers.
Raldow will report the findings in Session: SS 04 – PRO/QoL/Survivorship 1: New frontiers in affected person reported outcomes and survivorship on Sunday, Sept. 19 at 3:45pm EST in room 204.